Journal article
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis
Abstract
Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an …
Authors
Shefner JM; Cudkowicz ME; Hardiman O; Cockroft BM; Lee JH; Malik FI; Meng L; Rudnicki SA; Wolff AA; Andrews JA
Journal
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 20, No. 7-8, pp. 584–594
Publisher
Taylor & Francis
Publication Date
October 2, 2019
DOI
10.1080/21678421.2019.1612922
ISSN
2167-8421